Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that new preclinical data for the company’s LOXO-292 and LOXO-195 programs will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 – December 2, 2016 in Munich, Germany.

The details of the poster presentations are as follows:

LOXO-292

Date: December 1, 2016Title: The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancersSession: Molecular targeted agents IIAbstract Code: 441Poster Number: 120Location: Exhibition Hall

LOXO-195

Date: December 1, 2016Title: The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancersSession: Molecular targeted agents IIAbstract Code: 442Poster Number: 121Location: Exhibition Hall

About Loxo OncologyLoxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:Jacob S. Van NaardenChief Business Officerjake@loxooncology.com 

Investors:Peter RahmerThe Trout Group, LLC646-378-2973prahmer@troutgroup.com 

Media:Dan BudwickPure Communications, Inc.973-271-6085dan@purecommunicationsinc.com 

LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more LOXO ONCOLOGY, INC. Charts.
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more LOXO ONCOLOGY, INC. Charts.